Today we announced that three abstracts on intismeran autogene, our investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (@myESMO) Congress 2026, which will be held October 23–27 in Madrid, Spain. Read more:  #ESMO26#